Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Articles published by Boehringer Ingelheim Limited

News headline image
Boehringer Ingelheim introduces LENZELTA®: A new vaccine advancing mastitis prevention in dairy cows
From Boehringer Ingelheim Limited
Via GlobeNewswire
News headline image
Boehringer Ingelheim to evaluate innovative combination of DLL3‑targeting T‑cell engager plus PD‑L1/VEGF‑A bispecific antibody in small cell lung cancer
From Boehringer Ingelheim Limited
Via GlobeNewswire
News headline image
Ecuador Free of Rabies project accelerates progress toward eliminating dog-mediated rabies supported by Boehringer Ingelheim’s Stop Rabies program
From Boehringer Ingelheim Limited
Via GlobeNewswire
News headline image
Boehringer Ingelheim delivers on late-stage pipeline with two key launches, grows sales by 7.3%* in a successful 2025
From Boehringer Ingelheim Limited
Via GlobeNewswire
News headline image
Global survey reveals pet owners lack awareness of parasite risks and seek clearer prevention advice
From Boehringer Ingelheim Limited
Via GlobeNewswire
News headline image
FDA approves HERNEXEOS®, the first targeted therapy for adults with HER2-mutant advanced NSCLC as an initial treatment option
From Boehringer Ingelheim Limited
Via GlobeNewswire
News headline image
Boehringer Ingelheim licenses novel oral therapeutics program for immune diseases from Sitryx Therapeutics
From Boehringer Ingelheim Limited
Via GlobeNewswire
News headline image
Boehringer Ingelheim’s investigational asset apecotrep delivers proteinuria reduction in Phase II kidney trial
From Boehringer Ingelheim Limited
Via GlobeNewswire
News headline image
Boehringer Ingelheim and Simcere partner to advance a dual-target antibody treatment to address unmet needs in inflammatory bowel disease
From Boehringer Ingelheim Limited
Via GlobeNewswire
News headline image
Boehringer Ingelheim advances potential first-in-class IL-11 inhibitor to Phase II Clinical Research in Idiopathic Pulmonary Fibrosis
From Boehringer Ingelheim Limited
Via GlobeNewswire
News headline image
Boehringer Ingelheim announces clinical collaboration with Jazz Pharmaceuticals to advance HER2-targeted therapy in breast cancer
From Boehringer Ingelheim Limited
Via GlobeNewswire
News headline image
U.S. FDA approves JASCAYD® (nerandomilast) tablets for the treatment of progressive pulmonary fibrosis in adults
From Boehringer Ingelheim Limited
Via GlobeNewswire
News headline image
Boehringer Ingelheim announces appointment to Board of Managing Directors
From Boehringer Ingelheim Limited
Via GlobeNewswire
News headline image
Boehringer Ingelheim obtains two EU CVMP positive opinions for avian influenza vaccines VAXXITEK® HVT+IBD+H5 and VAXXINACT® H5
From Boehringer Ingelheim Limited
Via GlobeNewswire
News headline image
Boehringer Ingelheim and CDR-Life Expand Collaboration Efforts with Global Licensing Agreement for CDR111, an Antibody-Based Trispecific M-gager® for Autoimmune Diseases
From Boehringer Ingelheim Limited
Via GlobeNewswire
News headline image
Boehringer Ingelheim acquires license from Kyowa Kirin aimed at developing a novel treatment for patients with autoimmune diseases
From Boehringer Ingelheim Limited
Via GlobeNewswire
News headline image
JASCAYD® (nerandomilast) approved in China for the treatment of idiopathic pulmonary fibrosis (IPF)
From Boehringer Ingelheim Limited
Via GlobeNewswire
News headline image
Boehringer’s zongertinib demonstrated a 77% objective response rate in treatment-naïve patients with advanced HER2 (ERBB2)-mutant NSCLC
From Boehringer Ingelheim Limited
Via GlobeNewswire
News headline image
Boehringer Ingelheim advances cancer antibody-drug conjugate portfolio with asset from AimedBio
From Boehringer Ingelheim Limited
Via GlobeNewswire
News headline image
U.S. FDA approves Boehringer’s JASCAYD® (nerandomilast tablets) as first new treatment option for adults with IPF in over a decade
From Boehringer Ingelheim Limited
Via GlobeNewswire
News headline image
Boehringer Ingelheim launches new direct-to-consumer platform to expand patient access to important treatments
From Boehringer Ingelheim Limited
Via GlobeNewswire
News headline image
Boehringer’s HERNEXEOS® approved in China as first oral targeted therapy for previously treated patients with HER2-mutant advanced NSCLC
From Boehringer Ingelheim Limited
Via GlobeNewswire
News headline image
Boehringer Ingelheim and Palatin Technologies to develop potential first-in-class melanocortin receptor targeted treatment for patients with retinal diseases
From Boehringer Ingelheim Limited
Via GlobeNewswire
News headline image
U.S. FDA grants accelerated approval to Boehringer’s HERNEXEOS® as first orally administered targeted therapy for previously treated patients with HER2-mutant advanced NSCLC
From Boehringer Ingelheim Limited
Via GlobeNewswire
News headline image
Boehringer and Click Therapeutics’ investigational prescription digital therapeutic CT-155 meets primary endpoint in CONVOKE study for negative symptoms in schizophrenia
From Boehringer Ingelheim Limited
Via GlobeNewswire
News headline image
Boehringer Ingelheim and Re-Vana Therapeutics Announce Strategic Collaboration to Develop Long-Acting Ophthalmic Therapies
From Boehringer Ingelheim Limited
Via GlobeNewswire
News headline image
First half of 2025: Solid growth, investments and pipeline progress pave the way for two key launches in H2
From Boehringer Ingelheim Limited
Via GlobeNewswire
News headline image
Boehringer Ingelheim initiates Phase II study of BI 1815368, a potential first-in-class oral treatment for diabetic macular edema
From Boehringer Ingelheim Limited
Via GlobeNewswire
News headline image
Boehringer Ingelheim and Eko Health Inc. enter digital health collaboration to improve heart murmur detection in dogs
From Boehringer Ingelheim Limited
Via GlobeNewswire
News headline image
Boehringer Ingelheim to present early clinical evidence of innate immune modulation and anti-tumor activity via SIRPα blockade in two ongoing trials at ASCO 2025
From Boehringer Ingelheim Limited
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.